0001209191-21-011390.txt : 20210217
0001209191-21-011390.hdr.sgml : 20210217
20210217172809
ACCESSION NUMBER: 0001209191-21-011390
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210216
FILED AS OF DATE: 20210217
DATE AS OF CHANGE: 20210217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ostertag Eric
CENTRAL INDEX KEY: 0001765987
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39376
FILM NUMBER: 21646352
MAIL ADDRESS:
STREET 1: C/O POSEIDA THERAPEUTICS, INC.
STREET 2: 4242 CAMPUS POINT COURT, SUITE 700
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Poseida Therapeutics, Inc.
CENTRAL INDEX KEY: 0001661460
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 472846548
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-779-3100
MAIL ADDRESS:
STREET 1: 9390 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-16
0
0001661460
Poseida Therapeutics, Inc.
PSTX
0001765987
Ostertag Eric
C/O POSEIDA THERAPEUTICS, INC.
9390 TOWNE CENTRE DRIVE, STE 200
SAN DIEGO
CA
92121
1
1
1
0
Chief Executive Officer
Common Stock
2021-02-16
4
S
0
133149
10.0041
D
200696
I
See footnote
Common Stock
431590
D
Common Stock
629194
I
See footnote
Common Stock
3972217
I
See footnote
Common Stock
3645111
I
See footnote
Common Stock
961445
I
See footnote
The sales reported in this Form 4 were effected by Transposagen Biopharmaceuticals, Inc. ("Transposagen") pursuant to a Rule 10b5-1 trading plan established independently of Dr. Ostertag and in connection with a planned dissolution of Transposagen. Dr. Ostertag reports beneficial ownership of the shares held by Transposagen as a result of his affiliation with that entity.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held in the name of Transposagen, of which Dr. Ostertag is a majority stockholder.
The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person is a Trustee. The reporting person's minor daughter is the sole beneficiary of the Trust. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
/s/ Johanna Mylet, Attorney-in-Fact
2021-02-17